<DOC>
	<DOCNO>NCT00521365</DOCNO>
	<brief_summary>The primary purpose study assess efficacy Quetiapine extend release 600mg per day either monotherapy combined therapy treatment patient mania associate Bipolar disorder . This trial also assess life quality productivity loss improvement patient baseline day 21 .</brief_summary>
	<brief_title>Effectiveness Quetiapine XR Control Symptoms Manic Phase Bipolar Disorder .</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Affective Disorders , Psychotic</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Patients type I Bipolar Disorder Manic phase accord standard scale physician criterion . Patients gender , age 1865 year old first episode Patients chronic Bipolar Disorder least one previous manic episode 6 month inclusion , base physician experience manic episode study entry quality Psychoactive substance alcohol abuse dependence , forbidden medication , pregnancy , rapid cycling patient , intolerance Quetiapine , clinically severe disease , unstable Diabetes Mellitus , neutropenia , laboratory abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Bipolar Affective Psychosis</keyword>
	<keyword>Mania</keyword>
	<keyword>Manic Disorder</keyword>
	<keyword>Manic State</keyword>
</DOC>